Lateral lymph node dissection for low rectal cancer: Is it necessary?

Niki Christou, Jeremy Meyer, Christian Toso, Frédéric Ris, Nicolas Christian Buchs

Abstract
Rectal cancer constitutes a major public health issue. Total mesorectal excision has remained the gold standard treatment for mid and low rectal tumors since its introduction in the late 1980s. Removal of all lymph nodes located in the mesorectum has indeed improved pathological and oncological outcomes. However, when cancer spreads to the lateral lymph nodes (located along the iliac and obturator arteries) Western and Japanese practices differ. Where the Western guidelines consider this condition as an advanced form of the disease and use neoadjuvant radiochemotherapy liberally, the Japanese guidelines define it as a local disease and proceed to lateral lymph node dissection with or without neoadjuvant treatment. Herein, we review the current literature regarding both therapeutic strategies, with the aim of contributing to potential improvements in treatment and outcome for patients with low and mid rectal cancer.

Key words: Total mesorectal excision; Mesorectal resection; Lateral node metastasis; Extended lymphadenectomy
INTRODUCTION

Rectal cancer is ranked 8th among all cancers worldwide in terms of both incidence (3.9%) and mortality (3.2%), according to the latest data from GLOBOCAN 2018[1]. Although introduction of the total mesorectal excision (TME) treatment method[2] led to improved pathological and oncological outcomes—emerging as the gold standard surgical procedure—the treatment of mid and low rectal cancers remains challenging[3].

TME allows for the removal of perirectal lymph nodes, reducing the local recurrence rate from the pre-TME rates of 14%-40% down to 6.5%[4]; however, low and mid rectal cancer cells have the tendency to spread to lateral nodes, such as the internal iliac nodes, common iliac nodes, obturator nodes, and external iliac nodes[5]. Cases of metastases in these nodes reportedly range between 10.6% and 25.5% when the lateral lymph node dissection (LLND) has been performed for advanced rectal cancers (stages II-III)[6]. One of the main issues nowadays is what to do with these lateral nodes? While they are considered as regional metastatic nodes and surgically removed in Japan[7], they are defined as advanced disease in the West and lead to the use of neoadjuvant treatment[8].

LYMPHATIC DRAINAGE OF THE RECTUM

Lymphatic vessels of the rectum are formed from the lymphatic plexuses located in the rectal wall under the mucosa. Then, they reach the perirectal ganglia located in the mesorectum. After crossing the mesorectum, they form three trunks with nodal groups: the superior trunk drains into the rectosigmoid and forms the inferior mesenteric nodal groups; the middle trunk drains into the internal, external and common iliac lymph nodes and sacral nodes; and the inferior trunk drains into the superficial inguinal and external iliac lymph nodes, but also into the pelvic, sacral and internal iliac nodal groups. In case of cancer, its level of localization correlates to the risk of lymph node metastasis[9]. Moreover, rates of lymph node metastasis follow the depth of invasion and consequently the T stage[10,11].

The rectum is considered as a digestive segment, measuring around 15 cm in length and consisting of two parts: One covered by the peritoneum and one without peritoneum. However, there is no consensus regarding the definition of low rectum and, as a consequence, none for the localization of low rectal cancers. Traditionally, the rectum has been considered to be 15 cm long, as measured from the anal verge; however, Germany and the United States have defined the length as 16 cm and 12 cm, respectively[12]. Recently, the LOREC program of the United Kingdom (designed with the aim of improving low rectal cancer management[13]), proposed a magnetic resonance imaging (commonly known as MRI)-based anatomical definition. In such, low rectum is defined as the place “where the mesorectum tapers at the origin of the levators, at the pelvic sidewall” (around 6 cm from the anal verge).

On the other hand, in Japan, the classification depends on location of the tumor in relation to the peritoneal reflection, being either above (Ra) or below (Rb)[14]. However, it is most often an operative findings’ based-classification. It may be indeed difficult to achieve a correct preoperative assessment of the peritoneal reflection with the current imaging modalities.

LATERAL LYMPH NODE METASTASIS CONSTITUTES AN ONCOLOGICAL PREDICTOR

The latest tumor-node-metastasis classification (AJCC 8th edition)[15] considers lateral lymph node (LLN) involvement as indicating distant disease status. However, Japanese surgeons still acknowledge the presence of LLN involvement as a local disease, and consequently as a resectable disease[16]. Thus, in addition to TME, Japanese guidelines recommend performing systematic LLND when positive LLN(s) are suspected or in cases of stages II-III[16].
In addition, the presence of positive LLN(s) seems to be a prognostic factor not only for local recurrence but for overall survival as well. Indeed, in a retrospective study of 66 patients with stage I-III low rectal cancer treated with TME and LLND (without any neoadjuvant treatment), the presence of micro-metastatic LLN(s) was found to be significantly associated with reduced 10-year overall survival and recurrence-free survival[22].

In recent Japanese publications reporting on patients who underwent LLND for advanced low rectal cancer, the prevalence of LLN metastasis has ranged from 6%[23] to 50%[24]. This high heterogeneity in reported prevalence is in part due to bias in patient selection, with some of the research groups having performed systematic LLND[26] and others selective LLND based on preoperative imaging[27]. Recently, a systematic review and meta-analysis showed that MRI was accurate for the identification of LLN metastasis, with a pooled sensitivity of 0.72 and a pooled specificity of 0.80[28].

**TREATMENT OF METASTATIC LLNS**

Considering both prevalence of LLN metastasis and its negative impact on oncological outcomes, therapies should aim at treating LLN(s), especially in advanced cancer stages. In the 1950s, LLND was performed systematically for all rectal cancer cases but survival rates were not those expected and many complications, such as bleeding, were observed[29]. A 5-year survival rate of 54% was reported in patients treated with LLND as 46% of those who did not undergo systematic dissection; moreover, complications were more frequent and serious after LLND, including increased transfusion rate, prolonged hospital stay, and major urinary complications. A more recent Turkish cohort study showed an increase of 19% in urinary incontinence and 12% in urinary retention in patients with extended LLND compared to patients without[30]. Of note, similar findings were reported after preoperative radiotherapy alone[31]. From a sexual function point of view, this was confirmed in a Dutch cohort study, from which a decrease in sexual function was found to have occurred after preoperative radiotherapy[32]. These results are in accordance with Japanese data, which also showed worse sexual function after LLND[33].

Globally, the debate continues regarding the best management of patients with suspected LLN. Very recently, in a large multicenter study, Ogura et al[34] found that standard neoadjuvant treatment might be insufficient for preventing local recurrence in patients with advanced low rectal cancer (cT3/T4) and enlarged LLNs (defined as having a short axis of at least 7 mm). The authors reported that neoadjuvant radiochemotherapy plus TME plus LLND led to a 5-year lateral local recurrence rate of 5.7% (vs 19.5% without LLND). These results have to be taken cautiously as 19.5% local recurrence rate is unusual after randomized clinical trial (RCT) and TME. Also, the role of LLND in combination with neoadjuvant treatment could have been further explored. Also, the role of LLND in combination with neoadjuvant treatment should have been further explored. A recent Corean study[35] in which patients who had neoadjuvant CRT followed by standard TME (without LLND) were analysed to see whether they developed local recurrence in the lateral lymph node compartment. Out of 366 patients having benefited from neoadjuvant chemoradiotherapy and TME, 24 had lateral pelvic recurrence (6.6%); multivariate analysis showed that lateral pelvic recurrence was significantly associated with ypN and size of lateral lymph node. It has been suggested that the association of neoadjuvant RCT and TME might not be sufficient to prevent lateral recurrence in the case of obvious lateral lymph node metastases. Yet, the overall survival advantage of LLND is still under debate. In a recent systematic review and meta-analysis including 5502 patients, LLND did not improve the 5-year overall survival rate but instead led to higher rates of sexual and urinary dysfunctions, as compared to TME without LLND (odds ratio of 3.7)[36].

Based on these contradictory facts, Japanese surgeons continue performing LLND for advanced rectal cancer[37]. On the other hand, over the last 10 years, Japanese teams have tried to improve their results, not only by attempting to decrease the number of sexual and urinary complications through use of a nerve-sparing technique[38] but also by limiting the indications of LLND[39]. Since the 2000s, Japanese guidelines have recommended limiting LLND to tumors with a lower edge lying at or below the peritoneal reflection[40] and classified as cT3-4 with or without lymphatic node metastasis[41]. These adjustments have been shown beneficial in terms of both functional[42] and oncological outcomes[43]. A recent Japanese randomized controlled trial comparing TME with and without LLND for clinical stage II or III low rectal cancer demonstrated the two groups to have similar incidence for early urinary dysfunction (59% and 58% respectively)[44]. Considering oncological outcomes, Fujita...
et al.\textsuperscript{[39]} found 7.4% of patients treated with TME and LLND had local recurrences compared to 12.6% of the patients treated with TME without LLND ($P = 0.024$). Overall, both approaches have advantages and drawbacks. Specific strategies are needed when dealing with low rectal cancer, especially when a significant risk of LLN involvement is present.

**PERSPECTIVES**

Further research in this field is definitely needed, to precisely determine the prevalence of metastatic LLN\textsuperscript{[39]} and to identify the candidates for LLND. Subgroups of patients should be identified based on preoperative workup\textsuperscript{[8,39]}, to offer targeted therapies, including neoadjuvant radiochemotherapy and/or LLND, according to the risk of metastatic LLN. It is conceivable that a multistep treatment, including both of these therapeutic strategies, could be adopted consensually.

Imaging seems to constitute a key element in determining the aggressiveness of LLN. Thus, by combining radiologic, histologic and proteomic/genomic findings and using deep learning-machine (radiomics), we might develop a better prognostic model, leading to personalized therapeutic strategy\textsuperscript{[40]}. As a consequence, it is fundamental to have an expert colorectal unit being able to perform LLND with preservation of nerves.

**CONCLUSION**

To conclude, despite therapeutic improvements, rectal cancers remain a major health issue. TME is the gold standard to treat mid and low rectal tumors. However, Japan and Western guidelines differ as to the definition of when the cancer cells reach the LLN(s), applying LLND for the former and neoadjuvant treatment for the latter. With the Japanese approach, functional complications can occur but have been lessened by the recent emergence of the nerve-sparing technique, whereas it appears that neoadjuvant treatment exposes patients to long-term functional complications. Furthermore, local recurrence can occur after radiochemotherapy, especially when enlarged LLN(s) are found preoperatively in advanced low rectal cancers. Of note, the survival advantage of LLND remains to be demonstrated. Thus, considering both Western and Japanese strategies, it is necessary to focus more attention on the preoperative findings in order to better identify LLN involvement and offer LLND to the most appropriate, selected group of patients. Routine application of LLND is still a matter of debate, at least in Western countries, where liberal use of neoadjuvant radiochemotherapy remains the gold standard.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21402]
2. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg* 1982; 69: 613-616 [PMID: 6751457 DOI: 10.1002/brs.1800691019]
3. Aitken RJ. Mesorectal excision for rectal cancer. *Br J Surg* 1996; 83: 214-216 [PMID: 8689166 DOI: 10.1046/j.1365-2168.1996.02057.x]
4. Ahuja V. Open Surgical Techniques in Colorectal Cancer. In: Gearhart SL, Ahuja N, editors. Early Diagnosis and Treatment of Cancer Series. *Colorectal Cancer. Saint Louis: W.B. Saunders*; 2011; 145-165 [DOI: 10.1016/B978-1-4160-4686-8.30019-1]
5. Fujita S, Kotake K, Longo WE, Reddy V, Audisio RA. Lateral Lymph Node Dissection for Rectal Cancer. Longo WE, Reddy V, Audisio RA. Modern Management of Cancer of the Rectum. London: Springer London; 2015; 187-197 [DOI: 10.1007/978-1-4471-6609-2_13]
6. Watanabe T, Ishihara S, Chang GJ. Management of Lateral Pelvic Lymph Nodes. Chang GJ. *Rectal Cancer: Modern Approaches to Treatment*. Cham: Springer International Publishing; 2018; 213-230 [DOI: 10.1007/978-3-319-16384-0_13]
7. Akkoyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: Is it regional or distant disease? *Ann Surg* 2012; 255: 1129-1134 [PMID: 22549752 DOI: 10.1097/SLA.0b013e31825256f6]
8. van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blouwquist L, Beets-Tan RG, van
den Broek CB, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Kriekien JH, Marinjen CA, Henning G, Groot-Bosch J, Meldolesi J, Mróczkowski P, Nagtegaal I, Naredi P, Ortiz H, Pålman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Arieti C, Valenti V. EURECCA colorectal: Multidisciplinary management: European consensus conference colon amp; rectum. *Eur J Cancer* 2014; 50: 1-1.e34 [PMID: 24183379 DOI: 10.1016/j.euxca.2013.06.048]

9. **Frenkel JL**, Marks JH. Predicting the risk of lymph node metastasis in early rectal cancer. *Semin Colon Rectal Surg* 2015; 26: 15-19 [DOI: 10.1053/j.scrs.2014.10.000]

10. **Naschimbeni R**, Biergart L, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. *Dis Colon Rectum* 2002; 45: 200-206 [PMID: 11852333 DOI: 10.1016/s00124615(01)00347-7]

11. **Salinas HM**, Dursun A, Klos CL, Shellito P, Sylla P, Berger D, Bordeianou L. Determining the need for radical surgery in patients with T1 rectal cancer. *Arch Surg* 2011; 146: 540-543 [PMID: 21576608 DOI: 10.1001/archsurg.2011.76]

12. **Nelson H**, Petrelli N, Carlin A, Couture J, Fleshman J, Guillam J, Miedema B, Ota D, Sargent D; National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst* 2001; 93: 583-596 [PMID: 11309455 DOI: 10.1093/jnci/93.8.583]

13. **Daxil S**, Moran. LOREC: The English Low Rectal Cancer National Development Programme. *Bri J Hosp Med* 2013 [DOI: 10.12968/hmed.2013.74.7.337]

14. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Part II. Histopathological classification. Japanese Research Society for Cancer of the Colon and Rectum. *Jpn J Surg* 1983; 13: 574-598 [DOI: 10.1007/BF02469506]

15. **Weiser MR.** AJCC 8th Edition: Colorectal Cancer. *Ann Surg Oncol* 2018; 25: 1454-1455 [PMID: 29616422 DOI: 10.1007/s10434-018-6462-1]

16. **Watanabe T**, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saijo T, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murufushi K, Nakajima T, Oka S, Sakai Y, Tsugi A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itahashi M, Kitouma N, Morita T, Nishimura C, Tsutsui Y, Shimada Y. Randomized controlled trial and Lateral Pelvic Lymph Node Metastases. *Dis Colon Rectum* 1999; 52: 567-576 [PMID: 19404054 DOI: 10.1080/00058840131381499]

17. **Yano H**, Saijo T, Takeshita E, Miyake Y, Ishizuka N. Prediction of lateral pelvic node involvement in low rectal cancer by conventional computed tomography. *Br J Surg* 2007; 94: 1014-1019 [PMID: 17433377 DOI: 10.1002/bjs.5655]

18. **Masaki T**, Takayama M, Matsuoka H, Abe N, Ueki H, Sugiyama M, Tonari A, Kusuda J, Mizumoto S, Atony M. Intraoperative radiotherapy for oncological and function-preserving surgery in patients with advanced lower rectal cancer. *Langenbecks Arch Surg* 2008; 393: 173-180 [DOI: 10.1007/s00423-007-0260-8]

19. **Nagasaki T**, Akiyoshi T, Fujimoto Y, Komishi T, Nagayama S, Fukunaga Y, Ueno M. Preoperative Chemoradiotherapy Might Improve the Prognosis of Patients with Locally Advanced Low Rectal Cancer and Lateral Pelvic Lymph Node Metastases. *World J Surg* 2017; 41: 876-883 [PMID: 27730348 DOI: 10.1007/s00268-016-3748-y]

20. **Hoshino N**, Murakami K, Hida K, Sakamoto T, Sakai Y. Diagnostic accuracy of magnetic resonance imaging and computed tomography for lateral lymph node metastasis in rectal cancer: a systematic review and meta-analysis. *Int J Clin Oncol* 2019; 24: 46-52 [PMID: 30292177 DOI: 10.1007/s10147-018-1349-5]

21. **Stearns MW**, Deddish MR. Five-year results of abdominopelvic lymph node dissection for carcinoma of the colon and rectum. *Ann Surg Oncol* 2011; 18: 1847-1858 [PMID: 15774778 DOI: 10.1002/bjs.5665]

22. **Yamaguchi T**, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): Results from a multicentre, randomized controlled, non-inferiority trial. *Lancet Oncol* 2012; 13: 1014-1019 [PMID: 17433376 DOI: 10.1002/mon.20147]

23. **Kranenbarg EK**, Leer JW, Stiggelbout AM. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. *J Clin Oncol* 2005; 23: 1847-1858 [PMID: 15734778 DOI: 10.1200/JCO.2005.05.256]

24. **Fujita S**, Akatsu T, Mizusawa J, Saito N, Kimagasa Y, Kanemitsu Y, Ohme M, Fuji S, Shiozawa M, Yamaguchi T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Postoperative mortality and morbidity after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): Results from a multicentre, randomised controlled, non-inferiority trial. *Lancet Oncol* 2012; 13: 616-621 [PMID: 22591948 DOI: 10.1016/S1470-2045(12)71558-4]

25. **Opata A**, Komishi T, Cunningham C, Garcia-Aguiar J, Iversen H, Toda S, Lee JK, Lee HX, Uehara K, Lee P, Patter H, van de Velde CJH, Beets GL, Rutten HJT, Kusters M; Lateral Node Study Consortium. Neoadjuvant (Chem/o)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Local Lateral Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. *J Clin Oncol* 2019; 37: 33-43 [PMID: 30403572 DOI: 10.1200/JCO.18.00332]

26. **Kim TH**, Jeong SY, Choi DH, Kim DY, Jung KH, Moon SH, Chang HJ, Lim SB, Choi HS, Park JG. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. *Ann Surg Oncol* 2008; 15: 729-737 [PMID: 18057909 DOI: 10.1245/s10434-007-9696-x]

27. **Georgiou P**, Tan E, Gomis N, Antoniou A, Brown G, Nicholls RJ, Tekkis P. Extended lymphadenectomy...
versus conventional surgery for rectal cancer: A meta-analysis. *Lancet Oncol* 2009; 10: 1053-1062 [PMID: 19767239 DOI: 10.1016/S1470-2045(09)70224-4]

31 Koyama Y, Moriya Y, Hojo K. Effects of extended systematic lymphadenectomy for adenocarcinoma of the rectum—significant improvement of survival rate and decrease of local recurrence. *Jpn J Clin Oncol* 1984; 14: 623-632 [PMID: 6520971]

32 Moriya Y, Sugihara K, Akasu T, Fujita S. Nerve-sparing surgery with lateral node dissection for advanced lower rectal cancer. *Eur J Cancer* 1995; 31A: 1229-1232 [PMID: 7577028 DOI: 10.1016/0959-8049(95)00164-E]

33 Ishiguro M, Higashi T, Watanabe T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum Guideline Committee. Changes in colorectal cancer care in Japan before and after guideline publication: A nationwide survey about D3 lymph node dissection and adjuvant chemotherapy. *J Am Coll Surg* 2014; 218: 969-977.e1 [PMID: 24661852 DOI: 10.1016/j.jamcollsurg.2013.12.046]

34 Luzetti E, Pellino G, Nikolou S, Qin S, Mills S, Warren O, Tekkis P, Kontovouni sios C. Comparison of guidelines for the management of rectal cancer. *BJS Open* 2016; 2: 433-451 [PMID: 30511044 DOI: 10.1002/bjs5.88]

35 Ito M, Kobayashi A, Fujita S, Mizusawa J, Kanemitsu Y, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). *Eur J Surg Oncol* 2016; 44: 463-468 [PMID: 29428473 DOI: 10.1016/j.ejso.2018.01.015]

36 Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0121): A Multicenter, Randomized Controlled, Non inferiority Trial. *Ann Surg* 2017; 266: 201-207 [PMID: 28286057 DOI: 10.1097/SLA.0000000000002212]

37 Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. *J Clin Oncol* 2016; 34: 2157-2164 [PMID: 27138577 DOI: 10.1200/JCO.2015.65.9128]

38 Toiyama Y, Inoue Y, Shimura T, Fujikawa H, Saigusa S, Hiro J, Kobayashi M, Ohi M, Araki T, Tanaka K, Mohri Y, Kusunoki M. Serum Angiopoietin-like Protein 2 Improves Preoperative Detection of Lymph Node Metastasis in Colorectal Cancer. *Anticancer Res* 2015; 35: 2849-2856 [PMID: 25964566]

39 Konishi T, Shimada Y, Lee LH, Cavalcanti MS, Hsu M, Smith JJ, Nash GM, Temple LK, Guillem JG, Paty PB, Garcia-Aguilar J, Vakiani E, Gonen M, Shia J, Weiser MR. Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers. *Am J Surg Pathol* 2018; 42: 705-714 [PMID: 29624511 DOI: 10.1097/PAS.0000000000001059]

40 Madabhushi A, Lee G. Image analysis and machine learning in digital pathology: Challenges and opportunities. *Med Image Anal* 2016; 33: 170-175 [PMID: 27423409 DOI: 10.1016/j.media.2016.06.037]

41 Wang Z, Loh KY, Tan KY, Woo EC. The role of lateral lymph node dissection in the management of lower rectal cancer. *Langenbecks Arch Surg* 2012; 397: 353-361 [PMID: 22105772 DOI: 10.1007/s00423-011-0964-x]

42 Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane J. Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978-1997. *Arch Surg* 1998; 133: 894-899 [PMID: 9711965 DOI: 10.1001/archsurg.133.8.894]
